Agreement Focuses on Development of Next-Generation Biologics to Selectively Modulate T Cell Activity for the Treatment of Autoimmune Diseases CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma ™, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune diseases, today announced that Mary Simcox, Ph.D., will serve as the Vice President of
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 2017 BIO International Convention being
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc., an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, today announced that Kenneth Pienta, M.D., will serve as acting Chief Medical Officer
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologic therapeutics engineered to selectively target and modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the selection of its lead candidate, Cue-101,
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will present at the 5 th Annual Cancer Biopartnering &
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced the appointment of three new key opinion leaders to its
CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease, announced today that it will participate in this year's BIO CEO & Investor
Biologics Platform Targets T Cell-Mediated Diseases in Oncology and Autoimmunity Experienced Management Team, Board of Directors and Scientific Advisory Board Named CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Cue Biopharma , Inc. (Cue), an immunotherapy company developing biologics engineered to